Akari Therapeutics Plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
United Kingdom
Business Address
401 EAST JACKSON STREET, TAMPA, FL, 33602
Mailing Address
401 EAST JACKSON STREET, TAMPA, FL, 33602
Phone
(929) 274-7510
Fiscal Year End
1231
EIN
981034922
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 4, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 2, 2026 | View on SEC |
| S-1 IPO registration statement | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
Annual Reports
10-K
March 30, 2026
- Strategic acquisition of Peak Bio, Inc. adds Phase 2-ready oral drug PHP-303 to the pipeline.
- Diversified research portfolio now includes both nomacopan and PHP-303, targeting broader inflammatory conditions.
Material Events
8-K
Strategy Change
March 17, 2026
High Impact
- Aims to maintain Nasdaq listing, crucial for capital access and credibility.
- Higher share price post-split could attract institutional investors.
8-K
Strategy Change
December 16, 2025
High Impact
- Akari Therapeutics shareholders approved a 1-for-20,000 reverse stock split.
- Shareholders authorized the company's board to issue new shares until June 2030 for future capital raising.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.